Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen BarnettfiledCriticalAllen Barnett
Priority to ECSP972216priorityCriticalpatent/ECSP972216A/en
Publication of ECSP972216ApublicationCriticalpatent/ECSP972216A/en
Compuestos de piperazina di-N-sustituída o piperidina 1,4-di-sustituida de acuerdo con la fórmula I (incluyendo todos los isómeros sales, ésteres y solvatos). (gráfico), en donde R, R1, R2, R3, R4, R21, R27, R28, X, Y y Z son como se definen en la presente antagonistas mucarínicos útiles para el tratamiento de trastornos cognitivos como ser la enfermedad de Alzheimer. También se describe composiciones farmacéuticas y métodos de preparación, se describen además combinaciones de compuestos sinérgicas de la fórmula que figura anteriormente con inhibidores de acetilcolinesterasa.Compounds of di-N-substituted piperazine or 1,4-di-substituted piperidine according to formula I (including all salt, ester and solvate isomers). (graph), wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y and Z are as defined herein useful mucarinic antagonists for the treatment of cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also described, furthermore combinations of synergistic compounds of the formula given above with acetylcholinesterase inhibitors are described.
MUSCARINIC ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE OF SUCH MUSCARINIC ANTAGONISTS TO PREPARE MEDICINES FOR THE TREATMENT OF COGNITIVE DISORDERS, KIT FOR THE TREATMENT CONTAINING THEM